Saxenda (liraglutide), the daily GLP-1 injection, explained

What this guide covers

Saxenda is liraglutide, an older GLP-1 given as a once-daily injection and FDA-approved for weight management. How it works, why it is dosed every day rather than weekly, the titration and side effects, and how it compares to the newer weekly shots. This is patient education, not a substitute for the prescriber who knows your case. Generic names sit next to brand names throughout: semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound).

Key points

• The short answer. Saxenda is liraglutide, a GLP-1 receptor agonist given as a once-daily injection under the skin, made by Novo Nordisk and FDA-approved for chronic weight management in adults with obesity, or overweight with a weight-related condition, and in adolescents aged 12 and older. It was one of the first GLP-1 drugs approved for weight rather than diabetes, which makes it the older cousin of the weekly shots most people now talk about. The single fact that shapes the whole experience is the schedule: because liraglutide does not stay in the body as long as semaglutide or tirzepatide, Saxenda has to be injected every day, not once a week. Everything else, how it works and its side effects, will feel familiar if you have read about the newer drugs; the daily rhythm is what sets it apart.
• Same molecule as Victoza, dosed higher for weight. Liraglutide is sold under two different brand names for two different purposes, which is a common source of confusion. Victoza is liraglutide approved for type 2 diabetes at doses up to 1.8 mg daily, while Saxenda is the same molecule titrated to a higher 3.0 mg daily dose and approved specifically for weight management. It is the same relationship semaglutide has with Ozempic and Wegovy: one drug, two brands, two licensed uses, and a higher dose on the weight-management side. Knowing they are the same active ingredient helps explain why the side-effect profile and warnings carry across, and why you should never combine the two thinking they do different things.
• How it works, the familiar GLP-1 story. Saxenda works the same way the rest of the class does, by mimicking GLP-1, a gut hormone your body releases after eating. Activating the GLP-1 receptor slows how quickly the stomach empties, dampens appetite and the signals that drive hunger, and improves the way the body handles insulin and blood sugar after meals. The practical effect most people notice is feeling full sooner and staying full longer, which is what makes eating less feel less like a fight. This mechanism is identical in kind to Wegovy and Zepbound; the differences between the drugs are matters of how strongly and how long they act, not of doing something fundamentally different inside you.
• The daily routine and the dose climb. Like every GLP-1, Saxenda starts low and climbs slowly to limit the early nausea. The FDA label begins at 0.6 mg once daily for the first week, then increases by 0.6 mg each week, through 1.2, 1.8, and 2.4 mg, to the 3.0 mg daily maintenance dose usually reached at week five. The injection goes into the abdomen, thigh, or upper arm, and the pen delivers your set dose each day at whatever time is convenient, with or without food. The daily habit is the trade-off people weigh most: it means the drug is always on your mind in a way a weekly shot is not, but it also means a rougher day can be met with a short pause rather than a week-long one. The exact schedule and whether you reach the full dose is your prescriber's call against how you tolerate it.
• Side effects and the serious warnings. Because it is a GLP-1, Saxenda brings the class's familiar side effects: nausea leads the list, along with diarrhea, constipation, vomiting, and sometimes headache or fatigue, and they are usually heaviest in the first weeks and after each dose step. The management playbook is the same as for the weekly drugs, which is why our guides on nausea and constipation apply here too. Saxenda also carries the class warnings on its FDA label, including a boxed warning about thyroid C-cell tumors seen in rodent studies, so it should not be used by people with a personal or family history of medullary thyroid carcinoma or the syndrome MEN 2. The label further warns about pancreatitis, gallbladder disease and gallstones, low blood sugar when combined with insulin or a sulfonylurea, and, in children, changes in gallbladder function. These are uncommon, but they are why the drug is prescription-only and monitored.

Frequently asked questions